Biatrix

Quick links to important sections

Biatrix

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biatrix

Quick Facts: Biatrix (Quetiapine)

Property Description
Active Ingredient Quetiapine (as Fumarate salt)
Form Oral Tablets (Immediate-Release and Extended-Release)
Pharmacological Class Atypical Antipsychotic (Second-Generation Antipsychotic)
Common Use Stabilizing mood and regulating thought processes
Origin Synthetic compound (Dibenzothiazepine derivative)

What Type of Medicine is Biatrix?

Biatrix is a prescription-only medication whose active component is the synthetic compound Quetiapine, which acts on the central nervous system. It is specifically classified as an Atypical Antipsychotic, also known as a Second-Generation Antipsychotic (SGA). This classification designates Quetiapine as a drug that modulates the activity of key neurotransmitters in the brain, notably dopamine and serotonin.

Its chemical structure identifies it as a dibenzothiazepine derivative. The role of Quetiapine in mood stabilization has been clinically recognized through decades of pharmacological studies, establishing it as a key agent in its class.


Biatrix Composition and Available Forms

Biatrix is a single-component product whose therapeutic entity is Quetiapine, typically supplied as the salt Quetiapine Fumarate. This medicine is administered via the oral route in tablet form. Two principal physical forms are available: immediate-release tablets and specialized extended-release tablets (XR).

The extended-release formulation utilizes a specialized matrix to deliver Quetiapine gradually over an extended period. This gradual delivery allows for more stable levels of the active substance throughout the day, which is a key differentiating factor from its immediate-release counterpart.


What is the General Purpose of Atypical Antipsychotics?

The general purpose of Biatrix centers on achieving neural stability by helping to restore balance to neurotransmission. Its action involves receptor modulation, where the medicine binds to specific receptors (like dopamine D2 and serotonin 5-HT2A) to adjust abnormal signaling within the brain's pathways. This regulatory effect is generally intended to stabilize profound disturbances in thought, mood, and perception, serving a fundamental role in managing conditions related to emotional and psychological processing.

What side effects are possible with Biatrix?

Possible Side Effects and Safety Information

Biatrix (Quetiapine), as an atypical antipsychotic, is associated with a distinct set of officially documented adverse effects. Regulatory agencies classify these effects by frequency and system-organ class to formally describe the medicine’s safety profile.


Frequency-Classified Adverse Reactions

The most frequently observed effects, classified as Very Common (occurring in at least 1 in 10 patients), typically include somnolence, dizziness, dry mouth, and weight gain. Metabolic changes, such as elevations in serum triglyceride levels and total cholesterol, are also documented in this category.

Effects classified as Common include tachycardia, orthostatic hypotension, constipation, increased appetite, and hyperglycemia. Less frequent, Uncommon effects include seizure, Tardive Dyskinesia, QT prolongation, and hypersensitivity reactions.


Serious Adverse Reactions and Safety Patterns

The official labeling documents highlight several rare but serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), Agranulocytosis, and Venous Thromboembolism (VTE).

Safety notes specify risks for certain populations. In older adults being treated for dementia-related psychosis, an increased risk of death and cerebrovascular events is documented. Children and adolescents are noted for an increased risk of suicidal thoughts and behaviors, especially at treatment initiation, and a higher incidence of Extrapyramidal Symptoms (EPS).

Somnolence and orthostatic hypotension typically present during the initial dose-titration period, while Tardive Dyskinesia is associated with long-term exposure. Regulatory constraints require the regular monitoring of metabolic parameters (weight, blood glucose, and lipids) throughout the course of treatment.

Overdose and Emergency Response

The official regulatory profile for a Biatrix (Quetiapine) overdose is defined by the manifestation of serious central nervous system and cardiovascular effects. Documented presentations include pronounced somnolence, CNS depression, tachycardia (fast heart rate), and hypotension (low blood pressure). Severe outcomes that may occur include coma, respiratory depression, and QT prolongation, which is a potentially serious cardiac conduction abnormality.

Regulatory guidance requires patients to seek immediate medical attention and contact emergency services immediately upon any suspicion of overdose. Management must focus on intensive symptomatic and supportive care, as no specific antidote is known. Essential procedures mandated by regulatory bodies include establishing and maintaining a patent airway and instituting continuous cardiac monitoring due to the risk of dysrhythmias.

A special consideration is required for the Extended-Release (XR) formulation, which is associated with a delayed onset of toxicity and therefore requires a prolonged observation period. Furthermore, co-ingestion with other central nervous system depressant agents is explicitly noted as a factor that significantly increases the risk of severe poisoning. Treatment for hypotension must avoid epinephrine and dopamine to prevent paradoxical worsening of low blood pressure.

Therapeutic Uses of Biatrix

Biatrix (Quetiapine) is commonly used to provide essential therapeutic support across major psychiatric domains characterized by conditions involving episodic or fluctuating manifestations. It may assist in managing symptoms that interfere with daily functioning, contributing to easing the overall symptom load and supporting patient comfort.

Biatrix is relevant for treating Schizophrenia, Bipolar Disorder (including manic, mixed, and depressive episodes), and as an adjunctive treatment for Major Depressive Disorder (MDD) in adults.

It is often applied in clinical settings that involve acute or unstable symptom patterns, such as when positive symptoms like hallucinations and delusions are disruptive, or when extreme mood swings are more noticeable.

“This medication is commonly used to help manage symptoms associated with acute or episodic changes and symptoms that interfere with daily functioning.”

One key benefit is mood stabilization, which may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress and reducing the distressing intensity of these manifestations.


Quick Fact: Relief for Symptom Clusters

Domain Symptom Clusters Primary Benefit
Thought Disorders Hallucinations, Delusions, Disorganized thinking Supports Thought Regulation
Mood Disorders Mania, Bipolar Depression, Agitation Mood Stabilization

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Biatrix?

The official regulatory profile for Biatrix (Quetiapine) establishes specific population eligibility rules, defining both who may use the medicine and who is prohibited from using it.

Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults (18+ years) for all labeled indications. Adolescents (13–17 years) for Schizophrenia. Children/Adolescents (10–17 years) for Bipolar Mania.
Populations for whom use is not recommended Children and adolescents below 18 years (by some authorities) due to insufficient long-term data on development.
Populations for whom use is contraindicated Elderly patients with dementia-related psychosis (due to increased risk of death). Patients with known hypersensitivity to quetiapine or any component of the formulation.

Eligibility-Related Restrictions

Age-Related Rules: Safety and effectiveness are not established for Schizophrenia in patients under 13 years or Bipolar Mania in patients under 10 years. Older adults require a lower starting dose and slower titration due to reduced clearance. Hepatic impairment requires caution and a lower starting dose, while renal impairment does not require dosage adjustment. Use during pregnancy is permitted only if the potential benefit justifies the risk, and the neonate must be monitored if the drug is used in the third trimester. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Biatrix Interactions with other medicines and products

The interaction profile of Biatrix (Quetiapine) is primarily defined by its reliance on the CYP3A4 metabolic pathway and documented pharmacodynamic additive effects, as detailed in official government regulatory documents.

Contraindicated and Exposure-Altering Combinations

Co-administration with strong CYP3A4 inhibitors (e.g., azole-antifungal agents, HIV-protease inhibitors) is contraindicated because these agents significantly decrease Quetiapine clearance, leading to highly elevated plasma concentrations. Conversely, potent CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, St. John's Wort) increase Quetiapine's oral clearance, causing a marked reduction in plasma levels. Official regulatory constraints mandate strict dose adjustments when co-administering or discontinuing these enzyme inducers.

Pharmacodynamic and Administration Constraints

Biatrix carries a risk of additive effects when combined with other centrally acting agents, including alcohol, potentially augmenting effects such as central nervous system depression. Additionally, Quetiapine may add to the hypotensive effects of antihypertensive agents and may antagonize the effects of Levodopa and other dopamine agonists. For the extended-release formulation, regulatory documents state the tablet must be taken without food or with a light meal because a larger meal is formally documented to increase drug exposure.

Mechanism of Action

Biatrix initiates its mechanism of action by selectively binding to the A1alpha-receptor expressed on osteoclast precursors. This selective engagement is characterized by a high binding affinity, which initiates a specific downstream signaling cascade. The primary outcome of this interaction is the modulation of cellular differentiation signals, thereby influencing the dynamic equilibrium between osteoclast (bone resorption) and osteoblast (bone formation) activity.

The binding event triggers the inhibition of the JNK signaling pathway within the targeted cells. This molecular cascade leads to a resultant decrease in the synthesis and activity of the Cathepsin K enzyme. Cathepsin K is a cysteine protease responsible for cleaving specific bonds in type I collagen. By suppressing the activity of this enzyme, Biatrix effectively reduces the rate of enzymatic collagen degradation in the bone matrix.

The cumulative effect of these molecular interactions is the adjustment of the net skeletal remodeling rate. Specifically, the reduction in collagen degradation activity shifts the overall ratio of collagen synthesis to degradation within the bone microenvironment.

Dosage and Administration Information

How to Use Biatrix: Official Administration Guidelines

Biatrix (Quetiapine) is administered exclusively via the oral route as either an Immediate-Release (IR) or Extended-Release (XR) tablet. The official usage protocol requires two distinct phases: an initial titration period followed by a long-term maintenance dose. This graduated approach involves starting with a low dose and systematically increasing the amount over approximately four to six days until the recommended effective range is achieved.


Dosage Forms and Frequency

Formulation Dosing Frequency Meal Relationship
Immediate-Release (IR) Typically taken in divided doses two or three times daily May be taken with or without food
Extended-Release (XR) Taken once daily, preferably in the evening Must be taken without food or with a light meal (approx. 300 calories)

Administration Requirements

The standard adult dosing regimens for maintenance generally range from 150 mg/day to 800 mg/day, depending on the specific use pattern established during titration. For proper use, the XR tablets must be swallowed whole and must not be split, chewed, or crushed. Furthermore, specific usage protocols apply to certain populations. Older adults and individuals with hepatic (liver) impairment require a lower starting dose and a slower titration rate than the standard adult schedule. If treatment is stopped for one week or longer, the original titration schedule may need to be restarted to reinitiate therapy.

Recent Clinical Evidence

The information presented here describes the types of research conducted on Biatrix (Quetiapine), the areas that studies have monitored, and the limitations identified in the evidence. This summary uses language consistent with scientific uncertainty and is not intended to be clinical guidance.


Evidence for Use in Schizophrenia

Biatrix was studied for Schizophrenia using short-term Randomized Controlled Trials (RCTs) and studies observing patient status over longer intervals. These studies were used in research exploring how symptoms change over time, primarily measuring changes in hallucinations and delusions. Long-term studies monitored the frequency of recurring symptoms, sometimes lasting up to three years. Evidence is limited for outcomes extending far beyond these follow-up durations, and the evidence quality varies when examining certain symptoms, such as lack of motivation (negative symptoms).


Evidence for Use in Bipolar Disorder: Mania and Depression

Biatrix was evaluated in Bipolar Disorder, a condition where symptoms may vary in intensity. Studies explored Biatrix as both a single therapy and as an add-on treatment. For acute manic/mixed episodes, research monitored episodic changes over three to twelve weeks. For the depressive episodes, research examined acute changes in depressive symptoms and the frequency of shifts to mania. Follow-up durations were limited in most acute trials, meaning information about long-term effects is not fully established.


Evidence for Use in Major Depressive Disorder (MDD) (as Adjunctive Treatment)

Biatrix was evaluated in Adults with MDD who had an inadequate response to their initial antidepressant treatment. Research examined changes in overall depressive symptom scores over observation periods of eight to twelve weeks. Evidence is limited for long-term functional status in this specific adjunctive setting.


Long-Term Studies and Follow-up

Research explored outcomes related to use over extended time intervals. For some specialized extended-release formulation, comparative evidence is lacking, and there is limited information for long-term outcomes relative to the immediate-release version.


Evidence in Special Populations

Research explored Biatrix in Children and Adolescents (ages 10–17) with acute manic episodes and in Adolescents (ages 13–17) for Schizophrenia. The results apply only to the populations studied, and data for certain groups remain insufficient.


What is Still Uncertain About Biatrix Research

Key limitations include: follow-up durations were limited in many acute studies; long-term effects are not fully established; sample sizes were modest in some sub-population studies; and research findings were sometimes mixed when compared to a placebo. The research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes (Covers MDD adjunctive use and functional/QoL limitations)
  2. Quetiapine in children and adolescents with bipolar I disorder: a randomized, double-blind, placebo-controlled study (Source for pediatric data in Bipolar Mania)
  3. Quetiapine - StatPearls (NIH Reference outlining FDA-approved indications, doses, and clinical trial context)

Frequently Asked Questions (FAQ)

Common questions about Biatrix (FAQ)

Q: Is Biatrix a type of antibiotic, or something else?

Biatrix is the name for the medicine quetiapine, which official sources classify as an atypical antipsychotic. It is not an antibiotic. This means it works by affecting certain chemical messengers, or neurotransmitters, in the brain.

Q: Are the side effects of Biatrix permanent?

Most adverse effects are generally reversible upon stopping the medicine. However, official warnings note that antipsychotic medications carry a risk of a condition called tardive dyskinesia (TD), which involves uncontrolled body movements. This condition has the potential to become permanent in some people.

Q: What is the risk of having an allergic reaction to Biatrix?

Regulatory documents state that Biatrix (quetiapine) can cause allergic reactions, including rare but severe, life-threatening reactions such as anaphylaxis and angioedema. Signs like swelling of the face, tongue, or throat, hives, or trouble breathing are described as needing immediate medical attention. The official product information contains a complete list of severe reactions.

Q: How is Biatrix different from a steroid?

Biatrix (quetiapine) is classified as an atypical antipsychotic. It primarily acts on chemical signals in the brain, such as dopamine and serotonin, to exert its effects. Steroids are a different class of medicine that work by changing the body's hormones to reduce inflammation or affect the immune system.

Q: Is Biatrix safe for people with kidney problems?

Studies examining the use of Biatrix in people with severe renal impairment (kidney problems) indicate that the body's clearance of the medicine is reduced. Official labeling notes that while clearance is reduced, a specific starting dose adjustment is generally not required for those with renal impairment, which is different from guidance for those with liver problems.

Q: How long after stopping Biatrix does it stay in your system?

According to the official product information, the main drug compound, quetiapine, has an elimination half-life of approximately 7 hours. The active compound that the body creates from the drug has a slightly longer half-life, ranging from 9 to 12 hours. This time frame describes how long it takes for the drug to clear by half.

Q: Is there a generic version of Biatrix available?

Yes, official regulatory approval documents, such as the FDA's Orange Book, confirm that generic versions of the drug (known as Quetiapine Fumarate tablets) are available. This means that a version without the Biatrix brand name has been approved.

Q: Does Biatrix have any risk of addiction or dependence?

Biatrix (quetiapine) is not scheduled as a controlled substance under U.S. law. However, regulatory documents include a section on 'Drug Abuse and Dependence,' noting that misuse has been reported, and there is potential for withdrawal symptoms if the medicine is abruptly stopped.

Q: Are the side effects worse when first starting the medicine?

Official labeling describes a required titration period, meaning the dose is started low and slowly increased, which is a process designed to minimize initial side effects. This method helps to manage the early occurrence of common effects like drowsiness and changes in blood pressure, suggesting these effects may be more noticeable at the beginning of treatment.

Q: Does Biatrix affect blood sugar levels?

Yes, official warnings indicate that Biatrix can cause hyperglycemia (increases in blood sugar), which can sometimes be severe. Regulatory documents describe that monitoring of blood sugar levels is a recommended component of care for patients with existing diabetes or risk factors before and during therapy.

Q: What is the main reason Biatrix might be stopped by a doctor?

Official warnings and precautions identify conditions such as neuroleptic malignant syndrome (NMS) or severe allergic reactions as requiring prompt discontinuation of the medicine. Furthermore, the product has a boxed warning against use in elderly patients with dementia-related psychosis due to an increased risk of death, which is a key reason for non-use in that specific population.

Q: Can Biatrix make anxiety worse?

Official product information contains a warning that Biatrix (quetiapine) may cause new or increased feelings of anxiety, agitation, or other unusual changes in behavior. This warning is part of the required caution regarding the risk of suicidal thoughts or actions, especially when starting the medicine or when the dose is changed.

Q: Are there any special warnings for people with heart conditions using Biatrix?

Yes, regulatory documents note that Biatrix may cause an increase in the QTc interval, which is a measure of heart rhythm and carries a risk for arrhythmia (irregular heartbeat). Caution is officially advised for use in individuals with known cardiovascular disease, cerebrovascular disease, or conditions that can lead to low blood pressure.

Q: Is Biatrix available over-the-counter?

No, Biatrix (quetiapine) is officially classified as a prescription-only medication. It requires a valid prescription from a licensed healthcare provider and is not available for purchase over-the-counter.

Q: Does taking Biatrix affect fertility?

Official product information states that Biatrix can cause elevated levels of the hormone prolactin in some individuals. High prolactin levels (hyperprolactinemia) are associated with potential reproductive difficulties, including issues with becoming pregnant in both men and women.

Q: What is the pregnancy safety category for Biatrix?

The US FDA has phased out the old letter categories for pregnancy risk. The current labeling indicates that safety has not been established during pregnancy. It specifically warns that newborns exposed to the medicine during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms after delivery.

Q: Can Biatrix cause problems with vision?

Yes, official safety information reports that Biatrix has been associated with eye disorders, including blurred vision, as well as an association with cataract formation with long-term use. The official label notes that monitoring, such as regular eye examinations, is a recommended component of care due to this risk.

Q: Is Biatrix a controlled substance?

No, Biatrix (quetiapine) is not classified or scheduled as a controlled substance under the U.S. Controlled Substances Act. This means its prescribing and dispensing are not subject to the same strict controls as certain other medications.

How should Biatrix be stored and disposed of?

Official Storage and Disposal Instructions

Biatrix (quetiapine) tablets require specific conditions for storage and handling to maintain their stability, as documented by regulatory agencies.

Storage Requirement Regulatory Mandate
Temperature Range Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Do not freeze.
Environmental Protection Protect the tablets from moisture and light. Keep the container tightly closed and in the original container.
Child Safety Must be kept out of the sight and reach of children.

Disposal of Unused Product

Unused or expired Biatrix should be discarded according to official regulatory guidelines:

  • Preferred Method: Utilize a drug take-back program or an authorized collection site, where available.
  • Environmental Restriction: Do not dispose of this medicine via the household toilet or wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biatrix found in:

A-Z Index: